Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies
[Display omitted] Plant virus nanoparticles (PVNPs) have inherent immune stimulatory ability, and have been investigated as immune adjuvants to stimulate an anti-tumor immune response. The combination of immune stimulation, nanoparticle structure and the ability to deliver other therapeutic molecule...
Gespeichert in:
| Veröffentlicht in: | Seminars in cancer biology 2022-11, Vol.86 (Pt 2), p.1076-1085 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1085 |
|---|---|
| container_issue | Pt 2 |
| container_start_page | 1076 |
| container_title | Seminars in cancer biology |
| container_volume | 86 |
| creator | Shahgolzari, Mehdi Dianat-Moghadam, Hassan Fiering, Steven |
| description | [Display omitted]
Plant virus nanoparticles (PVNPs) have inherent immune stimulatory ability, and have been investigated as immune adjuvants to stimulate an anti-tumor immune response. The combination of immune stimulation, nanoparticle structure and the ability to deliver other therapeutic molecules provides a flexible platform for cancer immunotherapy. Researching multifunctional PVNPs and their modification will generate novel reagents for cancer immunotherapy. Here we review the properties of PVNPs, and their potential for clinical utilization to activate anti-tumor innate and lymphoid immune responses. PVNPs have potential utility for cancer immunotherapy as vaccine adjuvant, and delivery systems for other reagents as mono immunotherapy or combined with other immunotherapies. This review outlines the potential and challenges in developing PVNPs as cancer immunotherapy reagents. |
| doi_str_mv | 10.1016/j.semcancer.2021.07.018 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8821734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044579X21002121</els_id><sourcerecordid>S1044579X21002121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-44688e21273d71939b88fcbaf2d3746f917e830024081fa2949842177d38fb823</originalsourceid><addsrcrecordid>eNqFkMtq3DAUhkVpaJJpX6HVC9jRzZa8KYTQXCAlmwRCNkIjH0002LKR5CF9-2iYdmhXXR3B-b__iA-hb5TUlND2YlsnGK0JFmLNCKM1kTWh6gM6o6RrK9425OP-LUTVyO75FJ2ntCWEdIKKT-iUCy4byZoz9PJzGbJ3S7DZT8EMeB5MyHjn45JwMGGaTczeDpCwDzi_Ag7wlvEGAkSzR_Dk8OEj2I_jEqaSiWb2kD6jE2eGBF9-zxV6uv7xeHVb3T_c3F1d3ldWyCZXQrRKAaNM8l7SjndrpZxdG8d6LkXrOipBcUKYIIo6wzrRKcGolD1Xbq0YX6Hvh955WY_QWwg5mkHP0Y8m_tKT8frfTfCvejPttFKlpqhYIXkosHFKKYI7spTovW691Ufdeq9bE6mL7kJ-_fv0kfvjtwQuDwEoAna-4Ml6KD29j2Cz7if_3yPvU2mYLg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies</title><source>Elsevier ScienceDirect Journals</source><creator>Shahgolzari, Mehdi ; Dianat-Moghadam, Hassan ; Fiering, Steven</creator><creatorcontrib>Shahgolzari, Mehdi ; Dianat-Moghadam, Hassan ; Fiering, Steven</creatorcontrib><description>[Display omitted]
Plant virus nanoparticles (PVNPs) have inherent immune stimulatory ability, and have been investigated as immune adjuvants to stimulate an anti-tumor immune response. The combination of immune stimulation, nanoparticle structure and the ability to deliver other therapeutic molecules provides a flexible platform for cancer immunotherapy. Researching multifunctional PVNPs and their modification will generate novel reagents for cancer immunotherapy. Here we review the properties of PVNPs, and their potential for clinical utilization to activate anti-tumor innate and lymphoid immune responses. PVNPs have potential utility for cancer immunotherapy as vaccine adjuvant, and delivery systems for other reagents as mono immunotherapy or combined with other immunotherapies. This review outlines the potential and challenges in developing PVNPs as cancer immunotherapy reagents.</description><identifier>ISSN: 1044-579X</identifier><identifier>EISSN: 1096-3650</identifier><identifier>DOI: 10.1016/j.semcancer.2021.07.018</identifier><identifier>PMID: 34375725</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cancer immunotherapy ; Combination therapy ; In situ vaccination ; Molecular farming ; Nanoparticles ; Virus-like particle</subject><ispartof>Seminars in cancer biology, 2022-11, Vol.86 (Pt 2), p.1076-1085</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-44688e21273d71939b88fcbaf2d3746f917e830024081fa2949842177d38fb823</citedby><cites>FETCH-LOGICAL-c475t-44688e21273d71939b88fcbaf2d3746f917e830024081fa2949842177d38fb823</cites><orcidid>0000-0003-0624-974X ; 0000-0002-5946-6943</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1044579X21002121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34375725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shahgolzari, Mehdi</creatorcontrib><creatorcontrib>Dianat-Moghadam, Hassan</creatorcontrib><creatorcontrib>Fiering, Steven</creatorcontrib><title>Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies</title><title>Seminars in cancer biology</title><addtitle>Semin Cancer Biol</addtitle><description>[Display omitted]
Plant virus nanoparticles (PVNPs) have inherent immune stimulatory ability, and have been investigated as immune adjuvants to stimulate an anti-tumor immune response. The combination of immune stimulation, nanoparticle structure and the ability to deliver other therapeutic molecules provides a flexible platform for cancer immunotherapy. Researching multifunctional PVNPs and their modification will generate novel reagents for cancer immunotherapy. Here we review the properties of PVNPs, and their potential for clinical utilization to activate anti-tumor innate and lymphoid immune responses. PVNPs have potential utility for cancer immunotherapy as vaccine adjuvant, and delivery systems for other reagents as mono immunotherapy or combined with other immunotherapies. This review outlines the potential and challenges in developing PVNPs as cancer immunotherapy reagents.</description><subject>Cancer immunotherapy</subject><subject>Combination therapy</subject><subject>In situ vaccination</subject><subject>Molecular farming</subject><subject>Nanoparticles</subject><subject>Virus-like particle</subject><issn>1044-579X</issn><issn>1096-3650</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkMtq3DAUhkVpaJJpX6HVC9jRzZa8KYTQXCAlmwRCNkIjH0002LKR5CF9-2iYdmhXXR3B-b__iA-hb5TUlND2YlsnGK0JFmLNCKM1kTWh6gM6o6RrK9425OP-LUTVyO75FJ2ntCWEdIKKT-iUCy4byZoz9PJzGbJ3S7DZT8EMeB5MyHjn45JwMGGaTczeDpCwDzi_Ag7wlvEGAkSzR_Dk8OEj2I_jEqaSiWb2kD6jE2eGBF9-zxV6uv7xeHVb3T_c3F1d3ldWyCZXQrRKAaNM8l7SjndrpZxdG8d6LkXrOipBcUKYIIo6wzrRKcGolD1Xbq0YX6Hvh955WY_QWwg5mkHP0Y8m_tKT8frfTfCvejPttFKlpqhYIXkosHFKKYI7spTovW691Ufdeq9bE6mL7kJ-_fv0kfvjtwQuDwEoAna-4Ml6KD29j2Cz7if_3yPvU2mYLg</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Shahgolzari, Mehdi</creator><creator>Dianat-Moghadam, Hassan</creator><creator>Fiering, Steven</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0624-974X</orcidid><orcidid>https://orcid.org/0000-0002-5946-6943</orcidid></search><sort><creationdate>20221101</creationdate><title>Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies</title><author>Shahgolzari, Mehdi ; Dianat-Moghadam, Hassan ; Fiering, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-44688e21273d71939b88fcbaf2d3746f917e830024081fa2949842177d38fb823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer immunotherapy</topic><topic>Combination therapy</topic><topic>In situ vaccination</topic><topic>Molecular farming</topic><topic>Nanoparticles</topic><topic>Virus-like particle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shahgolzari, Mehdi</creatorcontrib><creatorcontrib>Dianat-Moghadam, Hassan</creatorcontrib><creatorcontrib>Fiering, Steven</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in cancer biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shahgolzari, Mehdi</au><au>Dianat-Moghadam, Hassan</au><au>Fiering, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies</atitle><jtitle>Seminars in cancer biology</jtitle><addtitle>Semin Cancer Biol</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>86</volume><issue>Pt 2</issue><spage>1076</spage><epage>1085</epage><pages>1076-1085</pages><issn>1044-579X</issn><eissn>1096-3650</eissn><abstract>[Display omitted]
Plant virus nanoparticles (PVNPs) have inherent immune stimulatory ability, and have been investigated as immune adjuvants to stimulate an anti-tumor immune response. The combination of immune stimulation, nanoparticle structure and the ability to deliver other therapeutic molecules provides a flexible platform for cancer immunotherapy. Researching multifunctional PVNPs and their modification will generate novel reagents for cancer immunotherapy. Here we review the properties of PVNPs, and their potential for clinical utilization to activate anti-tumor innate and lymphoid immune responses. PVNPs have potential utility for cancer immunotherapy as vaccine adjuvant, and delivery systems for other reagents as mono immunotherapy or combined with other immunotherapies. This review outlines the potential and challenges in developing PVNPs as cancer immunotherapy reagents.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34375725</pmid><doi>10.1016/j.semcancer.2021.07.018</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0624-974X</orcidid><orcidid>https://orcid.org/0000-0002-5946-6943</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-579X |
| ispartof | Seminars in cancer biology, 2022-11, Vol.86 (Pt 2), p.1076-1085 |
| issn | 1044-579X 1096-3650 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8821734 |
| source | Elsevier ScienceDirect Journals |
| subjects | Cancer immunotherapy Combination therapy In situ vaccination Molecular farming Nanoparticles Virus-like particle |
| title | Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T10%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multifunctional%20plant%20virus%20nanoparticles%20in%20the%20next%20generation%20of%20cancer%20immunotherapies&rft.jtitle=Seminars%20in%20cancer%20biology&rft.au=Shahgolzari,%20Mehdi&rft.date=2022-11-01&rft.volume=86&rft.issue=Pt%202&rft.spage=1076&rft.epage=1085&rft.pages=1076-1085&rft.issn=1044-579X&rft.eissn=1096-3650&rft_id=info:doi/10.1016/j.semcancer.2021.07.018&rft_dat=%3Celsevier_pubme%3ES1044579X21002121%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34375725&rft_els_id=S1044579X21002121&rfr_iscdi=true |